Asahi Kasei Pharma enters into exclusive license agreement for anti-CX3CR1 Antibody
The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.